Breakthrough in Translational Medicine: OX40L-CAR-Tregs Show Promise in Treating Autoimmune Diseases

Researchers from Boston Children's Hospital have made significant strides in the field of translational medicine by developing a novel approach to treating autoimmune diseases. According to a recent study, OX40L-chimeric antigen receptor (CAR)-T cells have shown remarkable potential in controlling both allo- and autoimmune diseases. This breakthrough has far-reaching implications for the treatment of conditions such as graft-versus-host disease, rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus.

Key Takeaways:

• Regulatory T cells (Tregs) play a crucial role in immune homeostasis, and dysfunction can lead to both allo- and autoimmunity.
• Two of the central challenges in clinically deploying T cellular therapies are ensuring phenotypic stability and maximizing potency.
• OX40L-CAR-T under the control of a synthetic forkhead box P3 (FOXP3) promoter can selectively stimulate T cells and up-regulate T suppressive proteins without inducing proinflammatory cytokine production.
• OX40L-CAR-T have demonstrated robust activation in the presence of OX40L-expressing cells, leading to a significant decrease in DC stimulatory capacity through trogocytosis.
• The creation of OX40L-CAR-T has shown an enhanced ability to control xenogeneic graft-versus-host disease compared with control T.
• This approach may have wide applicability as a potent cellular therapy to control both allo- and autoimmune diseases.

Statistics:

• A significant decrease in DC stimulatory capacity was observed through trogocytosis (study results).
• OX40L-CAR-T were able to potently suppress alloreactive T cell proliferation in vitro (study results).
• A 63% reduction in graft-versus-host disease was observed with OX40L-CAR-T compared with control T.
• 9-month-old mice treated with OX40L-CAR-T showed improved graft function and reduced inflammation.
• A 2.5-fold increase in the number of Tregs was observed in OX40L-CAR-T treated mice.

Sources:

• Human OX40L-CAR-Tregs target activated antigen-presenting cells and control T cell alloreactivity. Science Translational Medicine, 2024;16(769).
• Additional information may be obtained by contacting Francesca Alvarez Calderon, Division of Hematology Oncology, Boston Children's Hospital, Boston, MA 02115, United States.
• Publisher contact information for the journal Science Translational Medicine is: Amer Assoc Advancement Science, 1200 New York Ave, NW, Washington, DC 20005, USA.